Serial Number | 97371566 |
Word Mark | CTX131 |
Filing Date | Wednesday, April 20, 2022 |
Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
Status Date | Tuesday, June 18, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, April 23, 2024 |
Goods and Services | Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of hematologic malignancies; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy. |
Goods and Services | Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of hematologic malignancies; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of hematologic malignancies. |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, April 26, 2022 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, April 26, 2022 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | CRISPR Therapeutics AG |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 99 - Other |
Address | ZUG V8 6300 CH |
Party Name | CRISPR Therapeutics AG |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | ZUG V8 6300 CH |
Event Date | Event Description |
Saturday, April 23, 2022 | NEW APPLICATION ENTERED |
Tuesday, April 26, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Tuesday, February 7, 2023 | ASSIGNED TO EXAMINER |
Tuesday, February 14, 2023 | NON-FINAL ACTION WRITTEN |
Tuesday, February 14, 2023 | NON-FINAL ACTION E-MAILED |
Tuesday, February 14, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Thursday, May 11, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
Thursday, May 11, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
Monday, July 3, 2023 | ASSIGNED TO EXAMINER |
Thursday, August 10, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Thursday, August 10, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Friday, August 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Monday, October 2, 2023 | FINAL REFUSAL WRITTEN |
Monday, October 2, 2023 | FINAL REFUSAL E-MAILED |
Monday, October 2, 2023 | NOTIFICATION OF FINAL REFUSAL EMAILED |
Monday, December 18, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
Monday, December 18, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
Friday, February 16, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
Friday, February 16, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Friday, February 16, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Friday, March 15, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, April 3, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, April 23, 2024 | PUBLISHED FOR OPPOSITION |
Tuesday, April 23, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, June 18, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |